vs
Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.
C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $8.2M, roughly 1.3× NUSCALE POWER Corp). C4 Therapeutics, Inc. runs the higher net margin — -186.0% vs -3316.2%, a 3130.2% gap on every dollar of revenue. On growth, NUSCALE POWER Corp posted the faster year-over-year revenue change (1635.2% vs 112.8%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 22.4%).
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.
NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...
CCCC vs SMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.0M | $8.2M |
| Net Profit | $-20.5M | $-273.3M |
| Gross Margin | — | 32.9% |
| Operating Margin | -210.1% | -6532.9% |
| Net Margin | -186.0% | -3316.2% |
| Revenue YoY | 112.8% | 1635.2% |
| Net Profit YoY | 40.7% | -1465.5% |
| EPS (diluted) | $-0.09 | $-1.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.0M | — | ||
| Q3 25 | $11.2M | $8.2M | ||
| Q2 25 | $6.5M | $8.1M | ||
| Q1 25 | $7.2M | $13.4M | ||
| Q4 24 | $5.2M | $34.2M | ||
| Q3 24 | $15.4M | — | ||
| Q2 24 | $12.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $-20.5M | — | ||
| Q3 25 | $-32.2M | $-273.3M | ||
| Q2 25 | $-26.0M | $-17.6M | ||
| Q1 25 | $-26.3M | $-14.0M | ||
| Q4 24 | $-34.6M | $-75.0M | ||
| Q3 24 | $-24.7M | — | ||
| Q2 24 | $-17.7M | — | ||
| Q1 24 | $-28.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 52.4% | ||
| Q4 24 | — | 91.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -210.1% | — | ||
| Q3 25 | -306.4% | -6532.9% | ||
| Q2 25 | -441.0% | -534.9% | ||
| Q1 25 | -402.9% | -264.1% | ||
| Q4 24 | -728.4% | -34.6% | ||
| Q3 24 | -183.9% | — | ||
| Q2 24 | -178.6% | — | ||
| Q1 24 | -1060.2% | — |
| Q4 25 | -186.0% | — | ||
| Q3 25 | -286.4% | -3316.2% | ||
| Q2 25 | -402.6% | -219.0% | ||
| Q1 25 | -363.7% | -104.7% | ||
| Q4 24 | -667.8% | -219.1% | ||
| Q3 24 | -160.6% | — | ||
| Q2 24 | -147.6% | — | ||
| Q1 24 | -933.2% | — |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.44 | $-1.85 | ||
| Q2 25 | $-0.37 | $-0.13 | ||
| Q1 25 | $-0.37 | $-0.11 | ||
| Q4 24 | $-0.50 | $-0.77 | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.41 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $691.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $256.6M | $828.7M |
| Total Assets | $359.1M | $883.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | — | ||
| Q3 25 | $58.8M | $691.8M | ||
| Q2 25 | $78.2M | $420.7M | ||
| Q1 25 | $51.3M | $521.4M | ||
| Q4 24 | $55.5M | $441.6M | ||
| Q3 24 | $59.6M | — | ||
| Q2 24 | $73.1M | — | ||
| Q1 24 | $89.7M | — |
| Q4 25 | $256.6M | — | ||
| Q3 25 | $154.4M | $828.7M | ||
| Q2 25 | $174.1M | $692.9M | ||
| Q1 25 | $195.1M | $704.0M | ||
| Q4 24 | $216.0M | $618.7M | ||
| Q3 24 | $242.7M | — | ||
| Q2 24 | $247.1M | — | ||
| Q1 24 | $258.3M | — |
| Q4 25 | $359.1M | — | ||
| Q3 25 | $265.5M | $883.1M | ||
| Q2 25 | $296.5M | $606.5M | ||
| Q1 25 | $319.5M | $618.1M | ||
| Q4 24 | $349.6M | $544.7M | ||
| Q3 24 | $376.1M | — | ||
| Q2 24 | $381.1M | — | ||
| Q1 24 | $398.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.1M | $-199.8M |
| Free Cash FlowOCF − Capex | — | $-199.9M |
| FCF MarginFCF / Revenue | — | -2425.1% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.1M | — | ||
| Q3 25 | $-31.2M | $-199.8M | ||
| Q2 25 | $-12.1M | $-33.3M | ||
| Q1 25 | $-33.3M | $-22.8M | ||
| Q4 24 | $-17.9M | $-26.4M | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-18.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-31.6M | $-199.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-22.9M | ||
| Q4 24 | $-17.9M | $-26.5M | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -281.5% | -2425.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -170.9% | ||
| Q4 24 | -346.5% | -77.3% | ||
| Q3 24 | -157.2% | — | ||
| Q2 24 | -43.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.7% | 0.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCCC
Segment breakdown not available.
SMR
| Power Plant And NPM Engineering Design And Licensing Services And Fees | $8.0M | 97% |
| Other | $208.0K | 3% |
